Results 61 to 70 of about 267,471 (248)

Can Twitter be a source of information on allergy? Correlation of pollen counts with tweets reporting symptoms of allergic rhinoconjunctivitis and names of antihistamine drugs [PDF]

, 2015
Pollen forecasts are in use everywhere to inform therapeutic decisions for patients with allergic rhinoconjunctivitis (ARC). We exploited data derived from Twitter in order to identify tweets reporting a combination of symptoms consistent with a case ...
Carloni, E, D'Ambrosio, A, Fiocchi, A, Gesualdo, F, Pandolfi, E, STILO, GIOVANNI, Tozzi, Ae, VELARDI, Paola   +7 more
core   +1 more source

Long‐Term Real‐World Effectiveness of Rupatadine in Chronic Urticaria: A Retrospective Observational Study

JEADV Clinical Practice, EarlyView.
This retrospective observational study analyzed a cohort of chronic urticaria (CU) patients to provide insight into the clinical practice of CU with second‐generation antihistamines (SgAHs) and to evaluate the long‐term real‐world effectiveness of rupatadine in CU. Patients with chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU)
A. M. Giménez‐Arnau, C. Romero, M. March, A. Tomas, I. Izquierdo, R. M. Pujol   +5 more
wiley   +1 more source

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine [PDF]

, 2016
In the field of predictive, preventive and personalised medicine, researchers are keen to identify novel and reliable ways to predict and diagnose disease, as well as to monitor patient response to therapeutic agents.
A Acera, A Alonso, A Enríquez-de-Salamanca, A Enríquez-de-Salamanca, A Enríquez-de-Salamanca, A Ghaffariyeh, A Jemal, A Lambiase, A Lebrecht, A Lebrecht, A Leonardi, A Leonardi, A Leonardi, A Leonardi, A Leonardi, A Leonardi, A López-Miguel, A López-Miguel, A Peral, A Rentka, A Rentka, A Riemens, A Satici, A Solomon, AM Lemp, AP Smith, B Houser, B Li, B Ujhelyi, Biomarkers Definitions Working Group, BL Kolozsvári, C Aass, C Costagliola, C Galbis-Estrada, C Galbis-Estrada, C Joffre, C Lebrun, C Salvisberg, C Symeonidis, C Tamer, CG Begley, CM Cheung, CM Tanner, CS Paiva De, D Böhm, D Devos, D Huang, D Karamichos, D Pieragostino, D Pieragostino, D Pieragostino, DK Sen, E Csősz, E Nivenius, E Papavasileiou, E Toker, E Uchio, EA Mahmoud, EB Cook, EB Cook, EM Messmer, FH Grus, G Danaei, G Geerling, G Grech, G Martino, GU Kallarackal, GW Ousler, H Lam, H Link, HG Boersma, HJ Kim, HR Taylor, HV Nema, IA Mackie, J Jin, J Shoji, J Shoji, J Soria, J Tauber, J You, J You, JB Roedl, JC Pong, JC Pong, JE Moore, JF Huang, JG Ladas, JM Holopainen, JM Holopainen, JW Jung, K Cai, KC Yoon, KC Yoon, KK Nichols, KR VanDerMeid, KS Na, KS Park, L Cocho, L Tong, L Tong, L Zhou, L Zhou, L Zhou, M Börger, M Calonge, M Mavra, M Mrugacz, M Mrugacz, M Mrugacz, M Sacchetti, M Schicht, M Tesón, M Tishler, M Zandbelt, MA Lemp, MA Mowafy, MB Abelson, MB Goren, ME Stern, MH Jagasia, ML Massingale, N Boehm, N Boehm, N Dong, N Matheis, N Thun Und Hohenstein-Blaul von, N Tomosugi, O Golubnitschaja, O Golubnitschaja, OD Schein, P Aragona, P Argüeso, P Chhadva, P Versura, PG Montan, PK Coyle, PK Coyle, PS Goedegebuure, Q Guo, R Ihnatko, R Sack, R Shetty, R Sorkhabi, R Tailor, S Chotikavanich, S Darougar, S D’Souza, S Gutman, S Hagan, S Hagan, S Rusnak, S Vujosevic, S Yavuz, SA Lim, SC Pflugfelder, SF Hamm-Alvarez, SG Wu, SM Lam, SM Lam, SS Çomoğlu, SV Aluru, SY Lee, T Göncü, T Matsumura, T Nguyen-Khuong, T Peto, T Sakimoto, T Skwor, TH Wakamatsu, V Evans, VA Smith, VV Kapetanakis, W Choi, W Choi, W Liu, X Tan, Y Ogawa, Y Ohashi, YC Tham, YS Rabinowitz, Z Lei, Z Torok, Z Torok   +183 more
core   +2 more sources

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well‐Tolerated in a Pivotal Phase III Trial

Allergy, EarlyView.
A pivotal Phase III DBPC adaptive trial was conducted with PQ Grass 27600 SU. The primary endpoint EAACI‐CSMS0–6 demonstrated a highly significant, clinically meaningful improvement for PQ Grass of −0.27 points (95% CI: −0.42 to −0.12), corresponding to a relative difference of −20.3% (p = 0.0005) over placebo. Highly consistent secondary endpoints and
Stefan Zielen, Jonathan A. Bernstein, Gunter J. Sturm, Marek Jutel, Oliver Pfaar, the RESONATE Investigator Group, R. Gattringer, K. Gangl, J. Potesil, T. Sykora, M. Mattauchova, P. Panzner, M. Kasl, Z. Chovancova, T. Hofstetr, J. Poloniova, A. Zlamal, J. Haas, F. Heimlich, C. Korte, S. Ballenberger, J. Grosskopf, P. Heymer, C. Bergmann, M. Froer, G. Hoheisel, U. Thieme, C. Grigat, U. Schaefer, P. El Naib, A. Schwinn, S. Runge, M. Worm, S. Pauser, M. Jandl, J.‐C. Bohn, C. von Engelhardt, A. Schaefer, J. Rieker‐Schwienbacher, M. Cuevas, S. Lassmann, Y. Yarin, T. Nyeky, I. Szanyi, V. Urban, J. Nemes, P. Borowy, Z. Siergiejko, E. Janusik, B. Tluczykont, D. Madra‐Rogacka, S. Ptaczek, I. Wojciechowska, J. Orlicz‐Widawska, M. Żurowska‐Gębala, T. Hofman, S. Tokarski, M. Bederska, A. Latos, K. Kowal, E. Markut‐Miotla, E. Pisarczyk‐Bogacka, P. Kuna, B. Majorek‐Olechowska, A. Chmielewska, B. Kucinska, C. Chwala, P. Parikh, J. Sublett, J. Weiss, J. Leflein, P. Shapero, D. McNeil, K. O’Brien, E. Sher, G. Steven, L. Ford, A. Darter, L. Clore, D. Elkayam, G. Myers, J. Matz, M. Vanderwalker, S. Smiley, J. DeAngelo, A. Montanaro, J. Delgado, W. Greisner, C. Thornblade, M. Moss, Mohamed H. Shamji, Ralph Mösges, Markus Berger, Uwe E. Berger, Lawrence DuBuske, Janice A. Layhadi, Ludger Klimek, Markus Ollert, Murray A. Skinner, Matthias F. Kramer, Pieter‐Jan de Kam   +100 more
wiley   +1 more source

The Role of IgE in Crohn's Disease by Impairing the Capacity of Plasmacytoid Dendritic Cells to Generate FOXP3+ Tregs

Allergy, EarlyView.
We uncover an unprecedented role for IgE in CD. CD patients, regardless of allergic status and similar to allergic patients, display higher levels of circulating IgE+ and FcεRI+ immune cells, including pDCs, which are concomitant to fewer Tregs. In vitro experiments show that the anti‐IgE monoclonal antibody omalizumab restores the ability of pDCs from
Andrés de la Rocha‐Muñoz, Cristina Benito‐Villalvilla, David Olivares, Sofía Sirvent, Miguel A. García‐Brenes, Alba Angelina, Leticia Martín‐Cruz, Javier Cuesta, Paolo Tassinari, Xavier Jaumont, Carlos Taxonera, Oscar Palomares   +11 more
wiley   +1 more source

Recombinant Hypoallergenic Cat Allergy Vaccines

Allergy, EarlyView.
This study reports the construction and preclinical characterization of peptide‐carrier‐based vaccines combining all three important cat allergens (Fel d 1, Fel d 4 and Fel d 7) within single vaccine antigens, termed PreS‐Cat 1‐PreS‐Cat 5. Two subcutaneous immunizations of rabbits with PreS‐Cat 1‐5 induce equal or better antibodies blocking allergic ...
Daria Trifonova, Mirela Curin, Margarete Focke‐Tejkl, Zicheng Liu, Kristina Borochova, Pia Gattinger, Marianne van Hage, Hans Grönlund, Renata Kiss, Huey‐Jy Huang, Walter Keller, Ksenja Riabova, Antonina Karsonova, Michael Kundi, Inna Tulaeva, Daria Fomina, Alexander Karaulov, Rudolf Valenta   +17 more
wiley   +1 more source

A ‘look’ into conjunctivitis

South African Family Practice, 2019
Conjunctivitis is a common condition characterised by inflammation of the conjunctiva and is the most likely diagnosis in a patient with a red eye and discharge. Acute conjunctivitis is usually a self-limiting condition or one that is easily treated with
F. Kathrada
doaj   +1 more source

Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial

Allergy, EarlyView.
Different functions of an allergy app were tested for clinical benefit in a randomized, controlled trial in patients with grass pollen allergy. Participants with pollen forecast function took more medication and had fewer symptoms than participants without pollen forecast. A symptom forecast was developed based on the study data.
Caroline Holzmann, Johannes Karg, Matthias Reiger, Rajiv Kharbal, Paola Romano, Sabrina Scheiwein, Claudia Khalfi, Anna Muzalyova, Jens O. Brunner, Gertrud Hammel, Athanasios Damialis, Claudia Traidl‐Hoffmann, María P. Plaza, Stefanie Gilles   +13 more
wiley   +1 more source

TREATMENT OF CHILDREN'S ALLERGIC CONJUNCTIVITIS

Вопросы современной педиатрии, 2008
Allergic conjunctivitis is a widely spread disease, which is often accompanied with an allergic rhinitis. According to the up to date recommendations, the treatment of the allergic rhino conjunctivitis is based on 3 key principles: elimination of the ...
L.D. Ksenzova
doaj   +2 more sources

A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model [PDF]

, 2014
Background: The purpose of this study was to evaluate the efficacy and duration of action of once-daily dosing with alcaftadine 0.25% ophthalmic solution and olopatadine 0.2% ophthalmic solution as compared with placebo in the prevention of ocular ...
Ackerman, Stacey, Ciolino, Joseph B, D’Ambrosio, Francis, Greiner, Jack V, Hollander, David A, Villanueva, Linda   +5 more
core   +1 more source